Log In

New NMO Clinical Trial
Now enrolling at the Mayo Clinic
Mayo Clinics in Minnesota and Arizona have launched a new clinical trial for NMO patients. The purpose of the database is to determine if eculizumab, a monoclonal antibody that interferes with complement activation, reduces the frequency of NMO attacks or improves outcome.
The Primary Outcome Measures the reduction in number of NMO attacks and determines safety for NMO.The Secondary Outcome Measures improvement in the quality of life, visual function and walking, and determines drug levels in blood and CSF.
Experimental Drug Intervention:
The patient will receive eculizumab at a dose of 600mg intravenously (by infusion into the vein) each week for 4
weeks, 900mg intravenously at the fifth week, and 900mg every 2 weeks for 48 weeks.
The first infusion will be given at Mayo Clinic (Minnesota or Arizona); subsequent infusions will be administered at
home by a nurse employed by Coram Home infusion services (coordinated by a Study physician).
Eligibility
Patients must be NMO-IgG seropositive, and have a diagnosis of NMO (defined by 2006 criteria) or an NMO
spectrum disorder (recurrent optic neuritis or longitudinally extensive transverse myelitis).
Clinical evidence must document at least 2 relapses in the past 6 months or 3 relapses in the past 12
months (at least 1 relapse in the preceding 6 months).
The patient must be at least 18 years old.
If you are interested in this study and would like to learn more about it, please contact the investigators at the following locations:
Mayo Clinic - Arizona Principal Investigator: Dean M. Wingerchuk, M.D.
Contact: Irene Galasky 480-342-6104
Mayo Clinic - Minnesota Principal Investigator: Sean J. Pittock, M.D.
Contact: Karen Brekke 507-538-3761
Contact: Connie Brekke 507-266-3196
For more information please visit http:/
clinical trial, mayo clinic clinical trial, new clinical trial, nmo clinical trial
Last updated 840 days ago by Chief Moderator
A Rare Approach to a Rare Disease